No annual revenue total was found in Aprea Therapeutics, Inc.'s SEC filings.
Aprea Therapeutics, Inc. (APRE) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-14.14M
-8.5% vs year-ago TTM
Operating cash flow (TTM)
$-12.72M
+5.4% vs year-ago TTM
Free cash flow (TTM)
$-12.74M
EPS (TTM)
$-0.44
+79.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.45M
+108.5% vs prior year
Net cash
$52.89M
FY 2021
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Doylestown, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1781983
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$13.2M | -$14.3M | -$15.5M | — | — |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M |
| Diluted EPS | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 |
| Operating cash flow | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M |
| Free cash flow | — | -$13.6M | -$12.3M | — | — |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M |
| Total liabilities | — | — | — | $3.2M | $7.3M |
| Stockholders' equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M |
| Cash and investments | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M |
| Total debt | — | — | — | — | $190,471 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Aug 28, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 23, 2026 | Jul 23, 2026 |
All 446 Aprea Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.